June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
EP2 receptor agonist protects against trabecular meshwork apoptosis induced by ER stress
Author Affiliations & Notes
  • Thomas Debeir
    Ophthalmology, Sanofi, Paris, France
  • Georges Kalouche
    UMRS 968/INSERM/UPMC/CHNO des Quinze-Vingts, Institut de la Vision, Paris, France
    Unit of Translational Sciences, Sanofi, Chilly-Mazarin, France
  • Celine Boucher
    UMRS 968/INSERM/UPMC/CHNO des Quinze-Vingts, Institut de la Vision, Paris, France
  • Annick Coste
    Unit of Translational Sciences, Sanofi, Chilly-Mazarin, France
  • Christophe Baudouin
    UMRS 968/INSERM/UPMC/CHNO des Quinze-Vingts, Institut de la Vision, Paris, France
  • Xavier Vige
    Unit of Translational Sciences, Sanofi, Chilly-Mazarin, France
  • William Rostène
    UMRS 968/INSERM/UPMC/CHNO des Quinze-Vingts, Institut de la Vision, Paris, France
  • Footnotes
    Commercial Relationships Thomas Debeir, Sanofi (E); Georges Kalouche, Sanofi (E); Celine Boucher, Sanofi (F); Annick Coste, Sanofi (E); Christophe Baudouin, Sanofi (F); Xavier Vige, Sanofi (E); William Rostène, Sanofi (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1985. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Thomas Debeir, Georges Kalouche, Celine Boucher, Annick Coste, Christophe Baudouin, Xavier Vige, William Rostène; EP2 receptor agonist protects against trabecular meshwork apoptosis induced by ER stress. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1985.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Glaucoma is the second leading cause of blindness in the world characterized by the degeneration of retinal ganglion cells (RGCs) and optic nerve atrophy. Our aim is to provide insight into the potential involvement of mitochondrial impairment in the apparition and progression of the glaucomatous phenotype in DBA/2J mice.

Methods: Primary human TM cells were pretreated with vehicle control or butaprost acid or dibutyril cyclic AMP (dbcAMP) and then incubated with tunicamicyin 1 µg/ml. After 24h, TM cell viability was quantified by total ATP content (Celltiter-Glo) and DAPI stained nucleus count. Caspase 3/7 and 9 activations were analysed (caspase 3/7 and caspase 9-Glo) at 6h and 24h. Expression level of Bcl-2, Bax and phospho-Bad were analysed by western blot. Reactive oxygen species (ROS) accumulation were measured at 24h (ROS-Glo).

Results: Butaprost protected TM cell death induced by tunicamycin in a concentration dependent manner as analysed by increased ATP content and nucleus number at 24h. Furthermore, the prevention against cell death was due to inhibition of mitochondrial-dependent apoptosis as both executioner caspase 3/7 and caspase 9 activations were decreased by butaprost. These effects seems linked to increased cAMP as dbcAMP reproduced the same protection. Butaprost did not modify Bcl-2 and Bax level but increased phosphorylation of Bad. Finally, butaprost decreased ROS accumulation induced by tunicamycin.

Conclusions: Butaprost prevents TM cell from apoptosis induced by ER stress and increases anti-apoptotic phosphorylation of Bad. This protection is accompanied by a decrease in ROS accumulation. These results give insight in the function of EP2 signalling in the TM and are of importance in the development of prostaglandin analogues to lower the intraocular pressure.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×